Lercanidipino Tevagen (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels on vascular smooth‑muscle cells. By preventing calcium entry, it inhibits muscle contraction, causing arterial vasodilation. The resulting decrease in peripheral resistance leads to a reduction in systemic blood pressure.

The appropriate dose of Lercanidipino Tevagen is determined by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal function, and concomitant therapies. Dosage adjustments are made to achieve target blood‑pressure goals while minimizing side effects.

Safety data for lercanidipine in pregnancy and lactation are limited, and the product is not classified in a specific pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and a healthcare professional should be consulted.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class and offers a long‑acting vasodilatory effect. Compared with amlodipine, another dihydropyridine, lercanidipine may have a slightly lower incidence of peripheral edema, but both share similar efficacy in lowering blood pressure.

Lercanidipino Tevagen should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, arrhythmias, angioedema, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience symptoms such as faintness, chest pain, irregular heartbeat, swelling of the face or throat, or jaundice.

Lercanidipino Tevagen is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation, as well as in individuals with severe hypotension, cardiogenic shock, or unstable angina. Clinicians should evaluate each patient’s medical history before initiating therapy.